Loading organizations...
Arrowsmith Inc. is an early-stage biotechnology enterprise based in Tsukuba-shi, Ibaraki, Japan, that develops synthetic bacteriophage therapies designed to treat severe drug-resistant bacterial infections. The organization focuses its research and development efforts on combating global antimicrobial resistance by engineering targeted biological treatments for dangerous pathogens that no longer respond to conventional broad-spectrum antibiotics. Operating within the broader healthcare and infectious disease sectors, the firm pioneers specialized synthetic phage technologies intended for eventual clinical pharmaceutical applications and global commercialization. As a specialized life sciences startup, the company centers its primary operations on advancing a proprietary pipeline of alternative antimicrobial therapeutics through rigorous laboratory research and preclinical development programs. Arrowsmith was officially established in February 2025 by co-founder Hiroki Ando, who currently leads the organization as both its chief executive officer and chief scientific officer.
Arrowsmith has raised $2.0M across 1 funding round.
Arrowsmith has raised $2.0M in total across 1 funding round.
Arrowsmith has raised $2.0M in total across 1 funding round.
Arrowsmith's investors include Taira Kobayashi, JIC Venture Growth Investments.
Arrowsmith has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Pre-Series A in August 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 26, 2025 | $2M Seed Plus | Taira Kobayashi, JIC Venture Growth Investments | — | Announced |
